Sheikhalipour Zahra, Faghihdinevari Masood, Salehi-Pourmehr Hanieh, Khameneh Maryam, Vahedi Leila
Medical and Surgical Department, Nursing and Midwifery School, Organ Transplant Registry, Tabriz University of Medical Sciences, Iran.
Liver and Gastrointestinal Diseases Research Center, Organ Transplant Registry, Tabriz University of Medical Sciences, Tabriz, Iran.
Caspian J Intern Med. 2022;13(Suppl 3):161-172. doi: 10.22088/cjim.12.4.509.
Since the outbreak of COVID-19, various treatments have been frequently reported for patients infected with this virus, especially in transplant patients/recipients. Objective: Investigating of kidney transplant patients under immunosuppressive therapy infected with COVID-19 can pave the way to understanding, handling, and treatment of COVID-19.
We had a brief review of the literature on immunosuppressive therapy in kidney transplants infected with COVID-19. This was based on the PubMed Database with keywords "kidney, transplant, COVID-19, and immunosuppress" after hospitalization of kidney transplantation infected with COVID-19. He had already been recorded in the Organ Transplant Registry (ID≠ 64510) of Tabriz University of Medical Sciences /Iran.
We reported the clinical course of a 45-year-old man with a history of kidney transplantation and immunotherapy who was infected with COVID-19 with respiratory infections and positive RT-PCR (Real-time polymerase chain reaction). He was treated with hydroxychloroquine, Kaletra, CellCept, and prednisolone for 5 days, and finally discharged from the hospital. In addition, reviewing of 47 papers with 851 samples showed that immunosuppressant medications alone could be a therapeutic choice in kidney transplants infected with COVID-19 with careful management.
Patients with organ transplantation infected with COVID-19 may show different clinical signs, clinical course, and prognosis due to underlying diseases and the use of immunosuppressant medications. It might be best to continue taking the immunosuppressant medications but modify them based on the patients' conditions such as clinical symptoms, laboratory results, paraclinical examinations.
自新冠疫情爆发以来，针对该病毒感染患者的各种治疗方法屡有报道，尤其是在移植患者中。目的：对接受免疫抑制治疗的新冠病毒感染肾移植患者进行调查，可为了解、处理和治疗新冠病毒感染铺平道路。
我们简要回顾了关于新冠病毒感染肾移植受者免疫抑制治疗的文献。这是基于PubMed数据库，以“肾脏、移植、新冠病毒和免疫抑制”为关键词，检索新冠病毒感染肾移植患者住院后的相关文献。该患者已被录入伊朗大不里士医科大学器官移植登记处（ID≠64510）。
我们报告了一名45岁男性肾移植和免疫治疗病史患者的临床病程，该患者新冠病毒感染伴呼吸道感染，实时聚合酶链反应（RT-PCR）呈阳性。他接受了羟氯喹、克力芝、骁悉和泼尼松龙治疗5天，最终出院。此外，对47篇论文共851个样本的回顾显示，在谨慎管理的情况下，单独使用免疫抑制药物可能是新冠病毒感染肾移植患者的一种治疗选择。
新冠病毒感染的器官移植患者可能因基础疾病和免疫抑制药物的使用而表现出不同的临床体征、临床病程和预后。最好继续服用免疫抑制药物，但应根据患者的临床症状、实验室检查结果和辅助检查等情况进行调整。
